Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics

Xueli Xu; Shanbin Xu; Jipeng Wan; Diqing Wang; Xinlong Pang; Yuan Gao; Nengyi Ni; Dawei Chen; Xiao Sun

Bioactive Materials (Nov 2023)

Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics

Xueli Xu,
Shanbin Xu,
Jipeng Wan,
Diqing Wang,
Xinlong Pang,
Yuan Gao,
Nengyi Ni,
Dawei Chen,
Xiao Sun

Affiliations

Xueli Xu: School of Science, Shandong Jianzhu University, Jinan, 250101, China
Shanbin Xu: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China
Jipeng Wan: School of Science, Shandong Jianzhu University, Jinan, 250101, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China; Department of Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China; Department of Chemical and Biomolecular Engineering, National University of Singapore, 117585, Singapore
Diqing Wang: School of Science, Shandong Jianzhu University, Jinan, 250101, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China; Department of Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China; Department of Chemical and Biomolecular Engineering, National University of Singapore, 117585, Singapore
Xinlong Pang: School of Science, Shandong Jianzhu University, Jinan, 250101, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China; Department of Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China; Department of Chemical and Biomolecular Engineering, National University of Singapore, 117585, Singapore
Yuan Gao: School of Science, Shandong Jianzhu University, Jinan, 250101, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China; Department of Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China; Department of Chemical and Biomolecular Engineering, National University of Singapore, 117585, Singapore
Nengyi Ni: Department of Chemical and Biomolecular Engineering, National University of Singapore, 117585, Singapore
Dawei Chen: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China; Corresponding author.
Xiao Sun: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China; Corresponding author.

Journal volume & issue: Vol. 29
pp. 50 – 71

Abstract

Read online

Cytoskeleton plays a significant role in the shape change, migration, movement, adhesion, cytokinesis, and phagocytosis of tumor cells. In clinical practice, some anti-cancer drugs achieve cytoskeletal therapeutic effects by acting on different cytoskeletal protein components. However, in the absence of cell-specific targeting, unnecessary cytoskeletal recombination in organisms would be disastrous, which would also bring about severe side effects during anticancer process. Nanomedicine have been proven to be superior to some small molecule drugs in cancer treatment due to better stability and targeting, and lower side effects. Therefore, this review summarized the recent developments of various nanomaterials disturbing cytoskeleton for enhanced cancer therapeutics, including carbon, noble metals, metal oxides, black phosphorus, calcium, silicon, polymers, peptides, and metal-organic frameworks, etc. A comprehensive analysis of the characteristics of cytoskeleton therapy as well as the future prospects and challenges towards clinical application were also discussed. We aim to drive on this emerging topic through refreshing perspectives based on our own work and what we have also learnt from others. This review will help researchers quickly understand relevant cytoskeletal therapeutic information to further advance the development of cancer nanomedicine.

Published in Bioactive Materials

ISSN: 2452-199X (Online)
Publisher: KeAi Communications Co., Ltd.
Country of publisher: China
LCC subjects: Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials; Science: Biology (General)
Website: https://www.keaipublishing.com/en/journals/bioactive-materials/

About the journal

Abstract

Keywords